24 Hrs
Source:
Financial Times
Eli Lilly and Novo Nordisk boost profit forecast
Investors are concerned about Novo's heavy dependence on obesity treatments, causing a divergence in drugmakers' share prices.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)